[Ip-health] United States Patent: 9745368
james.love at keionline.org
Fri Sep 1 16:37:50 PDT 2017
Novartis and the University of Pennsylvania were granted a CAR T patent
on Tuesday, August 29. This patent, like others, discloses federal
Bayh-Dole rights in the invention.
It appears that Kymriah, the $475,000 Novartis CAR T treatment, will be
subject to royalty free and march-in rights, and a statutory obligation to
make the invention "available to the public on reasonable terms."
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
This invention was made with government support under PN2 EY016586 awarded
by the National Institutes of Health (NIH). The government has certain
rights in the invention.
US Patent Number
August 29, 2017
Targeting cytotoxic cells with chimeric receptors for adoptive
The present invention provides compositions and methods for regulating the
specificity and activity of T cells. In one embodiment, the invention
provides a type of chimeric antigen receptor(CAR) wherein the CAR is termed
a "KIR-CAR" which is a CAR design comprising a component of a receptor
naturally found on natural killer (NK) cells. In one embodiment, the NK
receptor includes but is not limited to a naturally occurring activating
and inhibitory receptor of NK cells known as a killer cell
immunoglobulin-like receptor (KIR).
Milone; Michael C. (Cherry Hill, NJ), Wang; Enxiu (Upper Darby, PA)
The Trustees of the University of Pennsylvania
The Trustees of the University of Pennsylvania (Philadelphia, PA)
Novartis AG (Basel, CH)
More information about the Ip-health